<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913948</url>
  </required_header>
  <id_info>
    <org_study_id>CTO 2168</org_study_id>
    <nct_id>NCT04913948</nct_id>
  </id_info>
  <brief_title>Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada</brief_title>
  <acronym>COPE</acronym>
  <official_title>Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to assess the mother-to-infant and potential vertical transmission of SARS-CoV-2&#xD;
      infection in pregnant women, maternal and neonatal biological samples will be prospectively&#xD;
      collected from women with confirmed or suspected COVID-19 at participating hospitals across&#xD;
      Ontario. Samples will be tested for the SARS-CoV-2 serology and viral load.&#xD;
&#xD;
      Outcomes for the study objective will be ascertained through the collection and testing of&#xD;
      biological samples from the mother and/or infant. Specifically the investigators will:&#xD;
&#xD;
        1. Assess maternal nasopharyngeal or oropharyngeal swab, vaginal mucosa, ano-rectal swab,&#xD;
           amniotic fluid, placenta (including subamniotic swab), breastmilk, cord blood and&#xD;
           neonatal nasopharyngeal swab for RNA particles of coronavirus, by ddPCR.&#xD;
&#xD;
        2. Assess maternal serum for anti-coronavirus antibodies, by immunoassay.&#xD;
&#xD;
        3. Examine the impact of coronavirus on the neonate with respect to serology and viral&#xD;
           load, in addition to placenta pathology findings and ddPCR.&#xD;
&#xD;
        4. Assess vertical transmission and the effect of coronavirus through placental pathology&#xD;
           examination using placental pathology synoptic report.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal and newborn viral titers</measure>
    <time_frame>At the time of delivery</time_frame>
    <description>Maternal and newborn viral titers as measured in the following sample types:&#xD;
i. Maternal nasopharyngeal/oropharyngeal, vaginal and rectal swabs ii. Newborn nasopharyngeal swabs iii. Placenta iv. Subamniotic placenta swabs v. Amniotic fluid vi. Breastmilk</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal and newborn antibody titers</measure>
    <time_frame>At the time of delivery</time_frame>
    <description>Maternal and newborn antibody titers as measured in the following sample types:&#xD;
i. Maternal blood ii. Cord blood iii. Amniotic fluid iv. Breastmilk v. Placenta</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Placental morphology and histopathology</measure>
    <time_frame>At the time of delivery</time_frame>
    <description>Placental morphology and histopathology using a standardized synoptic reporting framework for placental pathology. Specific outcomes that will be assessed are listed below:&#xD;
i. Maternal vascular malperfusion ii. Decidual vasculopathy iii. Implantation abnormalities iv. Intrauterine infection v. Placenta villous maldevelopment vi. Fetal vascular malperfusion vii. Chronic uteroplacental separation viii. Maternal-fetal interface disturbance ix. Chronic inflammation&#xD;
Each of the outcomes listed above will examined using the standardized grading scale developed within the reporting framework. The grading scale ranges from 0 (not present), 1 (mildly present or low-grade) and 2 (severely present or high-grade).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>SARS-CoV-2</condition>
  <condition>Covid19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Infectious Disease Transmission, Vertical</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Pregnant</arm_group_label>
    <description>Pregnant women with confirmed COVID-19 at any point during pregnancy or suspected (as identified at local hospital) of COVID-19 at time of delivery, who will be delivering at a participating hospital within Ontario</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Pregnant</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Should residual samples (i.e. maternal serum, umbilical cord serum, amniotic fluid, breast&#xD;
      milk, placental tissue [frozen and fixed]) remain after the purposes of the primary outcomes,&#xD;
      samples will be retained for 10 years for future, related REB approved studies.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women meeting the study eligibility criteria and delivering at a participating&#xD;
        hospital within Ontario will be recruited. Hospitals within the COPE Network include both&#xD;
        Level II and III hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with confirmed COVID-19 at any point during pregnancy or suspected&#xD;
             COVID-19 at time of delivery (as identified at local hospital) , who will be&#xD;
             delivering at one of the 13 participating hospitals within Ontario&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darine El-Chaar, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Romina Fakhraei, MSc</last_name>
    <phone>613-737-8899</phone>
    <phone_ext>73079</phone_ext>
    <email>rfakhraei@ohri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alysha Harvey, MSc</last_name>
    <phone>613-737-8899</phone>
    <phone_ext>73838</phone_ext>
    <email>alyharvey@ohri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L8E7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah McDonald, MD</last_name>
      <email>mcdonals@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Gervais</last_name>
      <email>ngerva@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sarah McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Gaudet, MD</last_name>
      <email>laura.gaudet@kingstonhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Pudwell, MSc, MPH</last_name>
      <email>jessica.pudwell@queensu.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Gaudet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand River Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Douglas, RN</last_name>
      <phone>519-749-4300</phone>
      <phone_ext>2351</phone_ext>
      <email>sheri.douglas@grhosp.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Blancher, NP</last_name>
      <phone>519-749-4300</phone>
      <email>patricia.blancher@grhosp.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sheri Douglas, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbra de Vrijer, MD</last_name>
      <email>barbra.devrijer@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Ryder</last_name>
      <email>jennifer.ryder@lhsc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Barbra de Vrijer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M2K1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elad Mei-Dan, MD</last_name>
      <email>elad.mei-dan@nygh.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Parvez Khatib</last_name>
      <email>parvez.khatib@nygh.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Elad Mei-Dan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre LaRoche, MD</last_name>
      <email>drandrelaroche@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Annum Hoque, BHs</last_name>
      <email>ahoque@hrh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Andre LaRoche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romina Fakhraei, MSc</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>73079</phone_ext>
      <email>rfakhraei@ohri.ca</email>
    </contact>
    <contact_backup>
      <last_name>Alysha Harvey, MSc</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>73182</phone_ext>
      <email>alyharvey@ohri.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Darine El-Chaar, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc-André Langlois, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Montfort</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1K0T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Palerme, MD</last_name>
      <email>stephaniepalerme@montfort.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>France Morin, IA, BSc, MSc</last_name>
      <phone>613-746-4621</phone>
      <email>francemorin@montfort.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Stéphanie Palerme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - Civic Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Dy, MD</last_name>
      <email>jdy@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Romina Fakhraei, MSc</last_name>
      <email>rfakhraei@ohri.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jessica Dy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Aviram, MD</last_name>
      <email>amir.aviram@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Susan O'Rinn</last_name>
      <phone>416-480-6100</phone>
      <email>susan.orinn@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Amir Aviram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Berger, MD</last_name>
      <email>howard.berger@unityhealth.to</email>
    </contact>
    <contact_backup>
      <last_name>Meagan Lacroix</last_name>
      <email>meagan.lacroix@unityhealth.to</email>
    </contact_backup>
    <investigator>
      <last_name>Howard Berger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Snelgrove, MD</last_name>
      <email>john.snelgrove@sinaihealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Hutchinson</last_name>
      <email>sarah.hutchinson@sinaihealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>John Snelgrove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD that underlie the results reported in this article, after deidentification, will be made available to other researchers upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

